Novartis says Kymriah receives second USFDA approval
Swiss drugmaker Novartis said on Tuesday it received a second approval from the U.S. Food and Drug Administration (FDA) for a second form of the blood cancer drug Kymriah.
The company said it received FDA approval to treat adult patients with relapsed or refractory large B-cell lymphoma.
"Today's FDA approval of Kymriah provides another opportunity for Novartis to build on its leadership in CAR-T development," said Liz Barrett, chief executive of Novartis Oncology.
Kymriah, a chimeric antigen receptor T cell (CAR-T) therapy, in August won FDA approval for treatment of acute lymphoblastic leukemia in patients up to 25 years old.
(Reporting by Ishita Chigilli Palli in Bengaluru; editing by Jonathan Oatis)
acute lymphoblastic leukemiaapprovalB-cell lymphomablood cancerCAR-Tchimeric antigen receptor T cellFDAKymriahLiz BarrettNovartisreceivesU.S. Food and Drug AdministrationUSFDA
Source : REUTERSNext Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd